Alnylam Pharmaceuticals Inc
ALNY251.560USD
+8.949+3.69%
Fechamento 04/25, 16:00（ET）Cotações atrasadas em 15 min
32.53BValor de mercado
PerdaP/L TTM
Mais detalhes de Alnylam Pharmaceuticals Inc Empresa
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Informações da empresa
Código da empresaALNY
Nome da EmpresaAlnylam Pharmaceuticals Inc
Data de listagemMay 28, 2004
Fundado em2003
CEODr. Yvonne L. Greenstreet, M.D.
Número de funcionários2230
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 28
Endereço675 W Kendall St
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142-1168
Telefone16175518200
Sitehttps://www.alnylam.com/
Código da empresaALNY
Data de listagemMay 28, 2004
Fundado em2003
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Phillip A. (Phil) Sharp, Ph.D.
Dr. Phillip A. (Phil) Sharp, Ph.D.
Independent Director
Independent Director
266.90K
--
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
99.04K
+16.58%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.03K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
136.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Phillip A. (Phil) Sharp, Ph.D.
Dr. Phillip A. (Phil) Sharp, Ph.D.
Independent Director
Independent Director
266.90K
--
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
99.04K
+16.58%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.03K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
--
Detalhamento da receita
Moeda: USDTempo de atualização: dom, 6 de abr
Moeda: USDTempo de atualização: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
Por RegiãoUSD
Nome
Receita
Proporção
United States
933.54M
41.52%
Europe
516.30M
22.96%
Net revenues from collaborations
510.22M
22.69%
Rest of World
196.39M
8.74%
Royalty revenue
91.79M
4.08%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
Acionista
Tempo de atualização: sex, 21 de fev
Tempo de atualização: sex, 21 de fev
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Capital World Investors
12.76%
The Vanguard Group, Inc.
10.04%
Fidelity Management & Research Company LLC
9.95%
Capital Research Global Investors
5.36%
BlackRock Institutional Trust Company, N.A.
5.19%
Other
56.70%
Estatísticas dos acionistas
Acionista
Proporção
Capital World Investors
12.76%
The Vanguard Group, Inc.
10.04%
Fidelity Management & Research Company LLC
9.95%
Capital Research Global Investors
5.36%
BlackRock Institutional Trust Company, N.A.
5.19%
Other
56.70%
Tipo
Acionista
Proporção
Investment Advisor
56.07%
Investment Advisor/Hedge Fund
32.20%
Corporation
3.44%
Hedge Fund
2.58%
Sovereign Wealth Fund
1.97%
Pension Fund
1.43%
Bank and Trust
1.19%
Research Firm
1.07%
Individual Investor
0.43%
Participação acionária institucional
Tempo de atualização: dom, 19 de jan
Tempo de atualização: dom, 19 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
1235
131.13M
100.81%
-458.58K
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
2023Q1
1116
123.13M
99.37%
-5.56M
2022Q4
1103
122.98M
99.27%
-3.16M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital World Investors
16.60M
12.76%
+92.10K
+0.56%
Dec 31, 2024
The Vanguard Group, Inc.
13.06M
10.04%
+378.83K
+2.99%
Mar 31, 2025
Fidelity Management & Research Company LLC
12.94M
9.95%
-1.20M
-8.49%
Dec 31, 2024
Capital Research Global Investors
6.97M
5.36%
+1.72M
+32.89%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.75M
5.19%
+149.81K
+2.27%
Dec 31, 2024
Regeneron Pharmaceuticals Inc
4.44M
3.42%
+4.44M
--
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
4.38M
3.37%
+1.25M
+39.67%
Dec 31, 2024
Wellington Management Company, LLP
4.20M
3.23%
-756.72K
-15.28%
Dec 31, 2024
Baillie Gifford & Co.
4.04M
3.11%
-846.74K
-17.33%
Dec 31, 2024
Dodge & Cox
3.54M
2.72%
-82.27K
-2.27%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
Tema Neuroscience and Mental Health ETF
4.39%
VanEck Biotech ETF
4.19%
Global X Genomics & Biotechnology ETF
3.91%
ProShares Ultra Nasdaq Biotechnology
3.49%
First Trust NYSE Arca Biotechnology Index Fund
3.23%
iShares Biotechnology ETF
3.11%
Invesco Nasdaq Biotechnology ETF
3.05%
Franklin Genomic Advancements ETF
2.56%
American Century Focused Dynamic Growth ETF
2.52%
SPDR S&P Biotech ETF
2.5%
Ver Mais
Tema Neuroscience and Mental Health ETF
Proporção4.39%
VanEck Biotech ETF
Proporção4.19%
Global X Genomics & Biotechnology ETF
Proporção3.91%
ProShares Ultra Nasdaq Biotechnology
Proporção3.49%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.23%
iShares Biotechnology ETF
Proporção3.11%
Invesco Nasdaq Biotechnology ETF
Proporção3.05%
Franklin Genomic Advancements ETF
Proporção2.56%
American Century Focused Dynamic Growth ETF
Proporção2.52%
SPDR S&P Biotech ETF
Proporção2.5%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados